SG11201606478YA - Modified meningococcal fhbp polypeptides - Google Patents

Modified meningococcal fhbp polypeptides

Info

Publication number
SG11201606478YA
SG11201606478YA SG11201606478YA SG11201606478YA SG11201606478YA SG 11201606478Y A SG11201606478Y A SG 11201606478YA SG 11201606478Y A SG11201606478Y A SG 11201606478YA SG 11201606478Y A SG11201606478Y A SG 11201606478YA SG 11201606478Y A SG11201606478Y A SG 11201606478YA
Authority
SG
Singapore
Prior art keywords
meningococcal fhbp
fhbp polypeptides
modified meningococcal
modified
polypeptides
Prior art date
Application number
SG11201606478YA
Inventor
Matthew Bottomley
Enrico Malito
Manuele Martinelli
Maria Scarselli
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of SG11201606478YA publication Critical patent/SG11201606478YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
SG11201606478YA 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides SG11201606478YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157399 2014-02-28
EP14177566 2014-07-17
PCT/EP2015/054174 WO2015128480A1 (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides

Publications (1)

Publication Number Publication Date
SG11201606478YA true SG11201606478YA (en) 2016-09-29

Family

ID=52596977

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606478YA SG11201606478YA (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides
SG10201907875TA SG10201907875TA (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201907875TA SG10201907875TA (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides

Country Status (23)

Country Link
US (3) US10392424B2 (en)
EP (2) EP3110442B1 (en)
JP (3) JP6786394B2 (en)
KR (2) KR20160127104A (en)
CN (1) CN106661092B (en)
AU (2) AU2015222121B2 (en)
BR (1) BR112016019735A2 (en)
CA (1) CA2940447C (en)
CY (1) CY1123622T1 (en)
DK (1) DK3110442T3 (en)
EA (1) EA034954B1 (en)
ES (1) ES2841378T3 (en)
HR (1) HRP20202080T1 (en)
HU (1) HUE052293T2 (en)
IL (1) IL247125B (en)
LT (1) LT3110442T (en)
MX (2) MX2016011176A (en)
PL (1) PL3110442T3 (en)
RS (1) RS61246B1 (en)
SG (2) SG11201606478YA (en)
SI (1) SI3110442T1 (en)
WO (1) WO2015128480A1 (en)
ZA (1) ZA201605534B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3110442T3 (en) 2014-02-28 2020-12-14 Glaxosmithkline Biologicals Sa MODIFIED MENINGOKOK-FHBP POLYPEPTIDER
BE1022641B1 (en) 2014-07-17 2016-06-23 Glaxosmithkline Biologicals Sa MENINGOCOCCAL POLYPEPTIDES fHbp MODIFIED
MX2017000775A (en) * 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Meningococcus vaccines.
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
IL303108B1 (en) * 2017-01-31 2024-03-01 Pfizer Neisseria meningitidis compositions and methods thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CA3131741A1 (en) 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
WO2022178196A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
JPH01125328A (en) 1987-07-30 1989-05-17 Centro Natl De Biopreparados Meningococcus vaccine
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0449958B9 (en) 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
US5334379A (en) 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (en) 1992-10-02 1994-05-02 Nederlanden Staat Outer membrane vesicle comprising a group of polypeptides which have at least the immune function of membrane bound outer membrane proteins (OMPs), method of preparation thereof and a vaccine comprising such an outer membrane vesicle.
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU755462B2 (en) 1997-08-21 2002-12-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1645631B1 (en) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Neisseria antigens and compositions
JP2004505885A (en) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Immunogenic β-propionamide linked polysaccharide-protein conjugates useful as vaccines produced using N-acryloylated polysaccharides
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
PL355178A1 (en) 1999-03-19 2004-04-05 Smithkline Beecham Biologicals S.A. Vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ES2477194T3 (en) 1999-04-30 2014-07-16 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens conserved
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
ATE460484T1 (en) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 KDA ANTIGEN OF NEISSERIA
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
KR100698561B1 (en) 2000-01-25 2007-03-21 더 유니버서티 어브 퀸슬랜드 Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha
BR0108711A (en) 2000-02-28 2004-06-22 Chiron Spa Heterologous expression of neisserial proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
BRPI0112928B1 (en) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
DK1490409T3 (en) 2002-03-26 2009-03-23 Novartis Vaccines & Diagnostic Modified saccharides with improved stability in water
ES2575014T3 (en) 2002-08-02 2016-06-23 Glaxosmithkline Biologicals S.A. Neisseria vaccine compositions comprising a combination of antigens
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2353608T3 (en) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L POLYPEPTID VACCINES FOR WIDE PROTECTION AGAINST HYPERVIRULENT MENINGOCOC LINES
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2004233012A1 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (en) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis
ES2522521T3 (en) 2005-09-05 2014-11-14 Glaxosmithkline Biologicals Sa Bactericidal serum assay for specific N. meningitidis antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
WO2011110635A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
ES2910199T3 (en) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Factor H-binding proteins (fHbp) with altered properties and methods of using them
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
BR112014004606A2 (en) 2011-08-31 2017-03-21 Children's Hospital & Res Center Oakland genetically modified sequences to facilitate antigen expression in neisseria and methods of use
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
BR112014021658A2 (en) 2012-03-09 2017-07-11 Pfizer neisseria meningitidis compositions and methods thereof
CN104602704B (en) 2012-06-14 2019-08-06 诺华股份有限公司 For the meningococcal vaccine of serum group X
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
DK3110442T3 (en) 2014-02-28 2020-12-14 Glaxosmithkline Biologicals Sa MODIFIED MENINGOKOK-FHBP POLYPEPTIDER
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
BE1022641B1 (en) * 2014-07-17 2016-06-23 Glaxosmithkline Biologicals Sa MENINGOCOCCAL POLYPEPTIDES fHbp MODIFIED
MX2017000775A (en) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Meningococcus vaccines.

Also Published As

Publication number Publication date
WO2015128480A1 (en) 2015-09-03
CN106661092A (en) 2017-05-10
HRP20202080T1 (en) 2021-02-19
US20170008933A1 (en) 2017-01-12
BR112016019735A2 (en) 2017-10-17
MX2020004419A (en) 2020-07-29
JP2021019629A (en) 2021-02-18
EP3110442B1 (en) 2020-10-14
CA2940447C (en) 2023-07-11
CY1123622T1 (en) 2022-03-24
CN106661092B (en) 2021-07-06
DK3110442T3 (en) 2020-12-14
US20190315812A1 (en) 2019-10-17
SG10201907875TA (en) 2019-09-27
EP3110442A1 (en) 2017-01-04
AU2015222121B2 (en) 2018-01-18
SI3110442T1 (en) 2021-01-29
EA201691429A1 (en) 2017-02-28
ES2841378T3 (en) 2021-07-08
AU2015222121A1 (en) 2016-10-13
US11021522B2 (en) 2021-06-01
EP3782643A1 (en) 2021-02-24
HUE052293T2 (en) 2021-04-28
JP2017512060A (en) 2017-05-18
MX2016011176A (en) 2017-02-23
EA034954B1 (en) 2020-04-10
JP2022177111A (en) 2022-11-30
LT3110442T (en) 2020-12-28
ZA201605534B (en) 2022-05-25
AU2018202431A1 (en) 2018-04-26
CA2940447A1 (en) 2015-09-03
US20210253647A1 (en) 2021-08-19
US11932671B2 (en) 2024-03-19
US10392424B2 (en) 2019-08-27
KR20230035455A (en) 2023-03-13
JP6786394B2 (en) 2020-11-18
IL247125B (en) 2021-12-01
RS61246B1 (en) 2021-01-29
KR20160127104A (en) 2016-11-02
IL247125A0 (en) 2016-09-29
PL3110442T3 (en) 2021-04-19

Similar Documents

Publication Publication Date Title
ZA201700170B (en) Modified meningococcal fhbp polypeptides
ZA201605534B (en) Modified meningococcal fhbp polypeptides
HK1216830A1 (en) Pillow
SG11201703111PA (en) Improved valve
GB2536850B (en) Pillow
AU358659S (en) Blender
IL245343B (en) Carbonation unit
GB2522293B (en) Rotary valve
ZA201701348B (en) New polypeptides
PL2902575T3 (en) Fitting configuration
HK1221128A1 (en) Blender
IL246533A0 (en) Novel polypeptides
PT3110442T (en) Modified meningococcal fhbp polypeptides
GB201400508D0 (en) Mutant polypeptides
AU358660S (en) Blender
GB201420332D0 (en) Power-bet blackjack
GB201419237D0 (en) Novel polypeptides
AP00957S1 (en) Blender
GB201410265D0 (en) Novel polypeptides
PL2899341T3 (en) Fitting configuration
GB201403024D0 (en) Polypeptides
GB201410184D0 (en) Odontalgic preparation
GB201421284D0 (en) Eazy peazy duvet cover
GB201405913D0 (en) Rotary Controller
TWM476553U (en) Multifunctional quilt